About this trial
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2. These pathogenic variants confer a higher risk of developing colorectal and other cancers, including small bowel cancer. The risk of developing a small bowel adenocarcinoma is about 100 times higher compared to individuals without Lynch syndrome, and the lifetime risk of small bowel cancer is estimated at 4,2%.
The diagnosis of a small bowel cancer depends on videocapsule endoscopy (VCE). This device is swalled so that it can record images of the small bowel, which are then stored on a wearable device for about 8 hours. The capsule is then expelled in the feces while the images are transferred to a computer to be analysed. To date, there is conflicting evidence on the efficacy of small bowel cancer screening with VCE
Rationale: this registry study will collect prospective data from patients with LS undergoing VCE
Aim: evaluate the incidence of neoplastic and pre-neoplastic lesions in patients with LS during a VCE-based small bowel cancer screening study
Design: this is a multicentric, observational study that analyzes data from diagnostic techniques already approved. Patients will not undergo diagnostic procedures beyond what would be recommended by clinical practice.
Eligibility criteria
Qualifiers
Pathogenic germline variant in one of the MMR genes (MLH1, MSH2/Epcam, MSH6, or PMS2).
Disqualifiers
Patients younger than 18 years of age
Patients unwilling or unable to provide informed consent
Patients with prior small bowel surgery
Patients with a contraindication to VCE
Trial design
Treatments tested in this trial
- Video capsule endoscopy
Treatment groups
Sponsors and collaborators
San Raffaele University
Lead sponsor
Unita' di Gastroenterologia - Policlinico Universitario di Bari
Collaborator
Centro di Riferimento Oncologico - Aviano
Collaborator
Humanitas Hospital, Italy
Collaborator